willytheg

Battery Research from Unexpected Sources - IBM

Anything to XYNH? Took a small pop a month ago on a news blurb.

Even Fatter Yields for Pfizer; M&A Targets in the Sector

Anybody out there follow a little biomed in Petaluma, CA named Oculus Innovative Sciences OCLS. From the DD I've done on the fundamentals of their product they are ripe for either a tenfold increase in pps or one of the bigger biotech companies are going to make ground floor execs and shareholders very wealthy.

They have developed a safe, inexpensive and effective platform to deal with MRSA, MSSA, VRE named "Microcyn". It's currently deployed or about to be deployed in China, India, and Mexico.

I'd love for somebody to check this out and tell me it's voodoo while it's still under $2/share. It was up 10% on the day the DJIA was down 773 last week.

Who Will Trigger E*Trade's Magic Moment - and a 111.4M Short Squeeze?

This is slightly off-topic but I'm hoping that I can get a lead from your readers.

I got a re-fi on a primary residence from etrade when they still had a loan origination dept. This loan came with many verbal assurances about how the terms of this loan would be improved down the road. About 2 weeks later Etrade stopped making loans and kept a skeleton dept. with severely curtailed hours open to service existing clients. This has made doing business associated with this loan extremely difficult. Needless to say, any verbal agreements on which I was depending, are out the window.

I was looking for something of a nationwide group of etrade home equity clients that may have had similar issues.

Thank you for allowing me to post this request and I apologize for any breach of protocol.

Saving SulphCo From Investor Confusion

It's good to hear about the "Harmonic Convergence" of the technology, management, and related issues. For the longest time this company has suffered some of the worst PR imaginable. On Yahoo alone, there are a dozen bashers posting under 5-8 pseudonyms. They are quite adept at the process of including a little fact, a little rumor, and a little embellishment to shred the pps. Other techniques I've seen used is "damning with faint praise", frequently comparing it to WSCE, a far more speculative company with far more distant prospects. This allows the shorts-most likely those who are bashing- to have a field day.

The Gunnerman's are gone, the process works, the general public is only dimly aware that the oil shortfall is in light, sweet crude and we are awash in "dirtier" oil which is SUFs feedstock.

They should be trumpeting this kind of news not only to analysts and business publications but to the hoi polloi who believe we are running out of oil.

Who handles-or better, doesn't handle-the publioc relations for this company? How much of the short interest do they comprise?

This should be a screaming buy short and long term. News taht would cause other companies to double gets a 5% rise in the pps of SUF.

PS. If you are going to flame rsvp., please try to use facts.
wgs

Likely Beneficiaries of Heavy Oil Production Technologies: Schlumberger, Imperial Oil

I'm suprised that the article made no mention of the sonocracking process patented by Sulphco (SUF) AMEX. This process has been used to increase the API of crude significantly. They have been plauged by inept management in the past but they have petro-savvy individuals in place now. They currently are going on line in the U.A.E. (Fujairah Oil Technologies), have completed a deal with So. Korea, and are implementing the process w/ O.M.V. in Austria.

Curiously, they seem to have attracted a sizeable bashing contingent, esp. on Yahoo. The founder of the company is the largest stockholder-though, thankfully, no longer running the company. These shares were often purchased on the open market and not all grants. That seems to be a vote of confidence.

As the article points out, we are quickly running out of light, sweet crude but remain awash in heavy oil. The management is no longer a joke and the implementation of the technology is further along than any other heavy oil process, SUF seems to be in the catbird seat of this sub-sector.

South Korea: 12 Ways to Invest in One of the Four Asian Tigers

I have been looking for a play on a Kosdaq equity-Seoul Semiconductor. I believe it's listed thought either never or rarely traded in the US as SFSOS. Short of owning this outright I've been looking for an ETF or Mutual Fund that has a position in this company. From the info. I have gathered, they are the world leaders in the white light producing LEDs with the most powerful and efficient technology.

Neuralstem: Wall Street Analyst Forum Presentation Transcript

I would like to comment on the role dopmine plays as an anti-depressant rather than its use in treating Parkinson's disease. The US is awash in serotonergics and noradrenergics so why no dopaminergics/ Does the FDA consider them too close to "street drugs"? I believe cocaine is actually a dopaminergic in that it inhibits the re-uptake of dopamine. Amphetamine on the other hand increases the amount of dopamine produced. The net result, in either case, is more bio-available dopamine. The effect of this greater availability of dopamine is characterized by greater focus, initiative, and vitality. That sounds like a pretty good goal for an anti-depressant if it could be achieved without the addictive considerations of tolerance and abuse.

Europe, as usual, seems to be far ahead of the US in developing an effective anti-depressant that takes advantage of dopamine's anti-depressant properties. They have an alternative to the SSRIs and SNRIs that are virtually the only choice most Americans suffering from depression have. Amineptine has been used widely throughout the EU for years and it now has a more refined sibling tianeptine-marketed as Stablon. Both of these medications allow more bio-available dopamine without the concerns around abuse. They seem to have some of the properties that a MAO inhibitor would have and some of the properties of a true dopaminergic. I have yet to find out why neither of these are available in the United States.

I am neither an MD nor a neurochemist so if someone with those credentials can dispute any of these assertions, by all means, feel free. I have, however, researched this topic pretty extensively.
wgs

Neuralstem: Wall Street Analyst Forum Presentation Transcript

I would like to comment on the role dopmine plays as an anti-depressant rather than its use in treating Parkinson's disease. The US is awash in serotonergics and noradrenergics so why no dopaminergics/ Does the FDA consider them too close to "street drugs"? I believe cocaine is actually a dopaminergic in that it inhibits the re-uptake of dopamine. Amphetamine on the other hand increases the amount of dopamine produced. The net result, in either case, is more bio-available dopamine. The effect of this greater availability of dopamine is characterized by greater focus, initiative, and vitality. That sounds like a pretty good goal for an anti-depressant if it could be achieved without the addictive considerations of tolerance and abuse.

Europe, as usual, seems to be far ahead of the US in developing an effective anti-depressant that takes advantage of dopamine's anti-depressant properties. They have an alternative to the SSRIs and SNRIs that are virtually the only choice most Americans suffering from depression have. Amineptine has been used widely throughout the EU for years and it now has a more refined sibling tianeptine-marketed as Stablon. Both of these medications allow more bio-available dopamine without the concerns around abuse. They seem to have some of the properties that a MAO inhibitor would have and some of the properties of a true dopaminergic. I have yet to find out why neither of these are available in the United States.

I am neither an MD nor a neurochemist so if someone with those credentials can dispute any of these assertions, by all means, feel free. I have, however, researched this topic pretty extensively.
wgs